About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in North Carolina | 20,428 Studies Near You | Clareo Health

Clinical Trials LocationsNorth Carolina

Clinical Trials in North Carolina

Discover 20,428 clinical trials near North Carolina. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 9581-9600 of 20,428 trials

COMPLETED25 miles

An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%

NCT00668655

The purpose of this study is to determine the cosmetic appearance of metronidazole gel (MetroGel®) 1% with commonly marketed facial foundations.

Galderma R&D30 participantsStarted Feb 2008

High Point, North Carolina, United States

COMPLETEDPhase 325 miles

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04124926

To evaluate the efficacy and safety of vonoprazan compared to lansoprazole in participants with erosive esophagitis.

Erosive Esophagitis

Phathom Pharmaceuticals, Inc.1,027 participantsStarted Oct 2019

Anniston, Alabama, United States • Athens, Alabama, United States • Birmingham, Alabama, United States +154 more locations

Find Trials by Condition in North Carolina

Breast Cancerin North Carolina Lung Cancerin North Carolina Prostate Cancerin North Carolina Colorectal Cancerin North Carolina Melanomain North Carolina Leukemiain North Carolina Lymphomain North Carolina Pancreatic Cancerin North Carolina Ovarian Cancerin North Carolina Brain Cancerin North Carolina

Data from ClinicalTrials.govTerms

WITHDRAWNPhase 441 miles

Non-Responsive Diabetic Macular Edema and Spironolactone

NCT04853355

Diabetic patients with macular edema and choroidal hyperpermeability (as manifested as a thick choroid on OCT (optical coherence tomography) and ICG hyperfluorescence on ICG) unresponsive to anti-VEGF (vascular endothelial growth factor) and steroid injections will be treated with spironolactone in addition to the continued treatment of anti-VEGF injections, specifically aflibercept (Eylea).

Diabetic Maculopathy

Wake Forest University Health SciencesStarted Jul 2022

Winston-Salem, North Carolina, United States

COMPLETEDPhase 246 miles

Bicalutamide in Treating Patients With Metastatic Breast Cancer

NCT00468715

RATIONALE: Androgens can cause the growth of breast cancer cells. Antihormone therapy, such as bicalutamide, may stop the adrenal glands from making androgens. PURPOSE: This phase II trial is studying how well bicalutamide works in treating patients with metastatic breast cancer.

Memorial Sloan Kettering Cancer Center28 participantsStarted Mar 2007

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States +5 more locations

COMPLETED46 miles

COVID-19 Antibody Levels After Vaccines

NCT04944134

This study will measure the levels of nasal mucosal Immunoglobulin A (IgA) and blood serum IgA up to one year after COVID vaccination, as well as examining what factors might affect antibody levels in the nose. This will be done through nasal epithelial lining fluid collection and standard venipuncture.

Vaccine Preventable Disease

University of North Carolina, Chapel Hill71 participantsStarted Jun 2021

Chapel Hill, North Carolina, United States

COMPLETEDPhase 357 miles

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT03602560

A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA) The participants might enter the ongoing open-label safety study (NCT03301506) following this double-blind study.

Primary Biliary Cholangitis

Gilead Sciences265 participantsStarted Oct 2018

Chandler, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +153 more locations

TERMINATEDPhase 1/257 miles

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT01464034

This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.

Multiple Myeloma

Criterium, Inc.136 participantsStarted Nov 2011

Atlanta, Georgia, United States • Indianapolis, Indiana, United States • Hackensack, New Jersey, United States +6 more locations

UNKNOWNPhase 166 miles

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

NCT04798001

This study evaluates an investigational vaccine that is designed to protect humans against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease. The investigational vaccine, MV-014-212, is a live attenuated vaccine against respiratory syncytial virus (RSV) that is expressing the spike (S) protein of SARS-CoV-2. MV-014-212 is administered as drops or a spray in the nose. Specifically, this study analyzes the safety of, and the immune response to, the vaccine when administered to healthy adults between the ages of 18 and 69 years who are seronegative to SARS-CoV-2 and have not received a prior vaccine against COVID-19.

Meissa Vaccines, Inc.130 participantsStarted Apr 2021

Lenexa, Kansas, United States • Raleigh, North Carolina, United States

UNKNOWNNA66 miles

USCRI READY4Life Program

NCT05476185

The U.S. Committee for Refugees and Immigrants (USCRI) has developed the Relationships, Education, Advancement, and Development for Youth for Life (READY4Life) Program. This is a 16-hour program for immigrants/refugees, ages 14 to 24. The program is designed to help young immigrants and refugees prepare for a successful life in the United States. The program is taught by USCRI program staff and is being implemented at eight sites across the U.S.: Cleveland, Ohio; Colchester, Vermont; Des Moines, Iowa; Miami, Florida; Philadelphia, Pennsylvania; Raleigh, North Carolina; Saint Paul, Minnesota; and Twin Falls, Idaho. The project also includes a rigorous evaluation component, featuring a Randomized Control Trial (RCT) design.

CommunicationProblem SolvingSocial Relationships+1 more

US Committee for Refugees and Immigrants4,800 participantsStarted Feb 2022

Washington D.C., District of Columbia, United States • Miami, Florida, United States • Twin Falls, Idaho, United States +6 more locations

COMPLETED84 miles

LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices

NCT02091011

The study is to determine the rate and cause of device replacements at 5 years post-implantation. It will assess the battery and device longevity of the Implantable Cardioverter Defibrillators (ICD) and CRT-D Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices. It will also validate the device survival information given in Boston Scientific's Product Performance Report by comparing the pulse generator (PG) survival probability in the study to that presented in the Product Performance Reports (PPR)

Implantable Cardioverter DefibrillatorsCRT-D Cardiac Resynchronization Therapy Defibrillator

Boston Scientific Corporation1,600 participantsStarted Jan 2014

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Glendale, Arizona, United States +77 more locations

COMPLETEDPhase 3181 miles

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

NCT02547441

This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.

Maruho Co., Ltd.463 participantsStarted Dec 2015

Fremont, California, United States • Miami, Florida, United States • Miramar, Florida, United States +38 more locations

UNKNOWNPhase 1182 miles

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

NCT04909021

This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.

Respiratory Syncytial Virus (RSV)

Meissa Vaccines, Inc.63 participantsStarted Jun 2021

Phoenix, Arizona, United States • La Mesa, California, United States • Atlanta, Georgia, United States +9 more locations

TERMINATEDPhase 2197 miles

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

NCT03452540

The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess the efficacy and safety of orally administered DS102 in adult patients with acute decompensated alcoholic hepatitis

Severe Acute Decompensated Alcoholic Hepatitis

Afimmune9 participantsStarted Nov 2018

Miami, Florida, United States • Miami, Florida, United States • Kansas City, Kansas, United States +5 more locations

COMPLETEDPhase 4213 miles

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne

NCT00469755

To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0.1% followed by 6 weeks of treatment with Tazorac Cream

Galderma R&D302 participantsStarted Feb 2006

San Diego, California, United States • Detroit, Michigan, United States • Fridley, Minnesota, United States +9 more locations

UNKNOWNNA263 miles

Time-Restricted Eating With Exercise

NCT05486702

The purpose of the study is to determine if body composition differs between early time restricted eating (8-hour feeding period from 7 am to 3 pm) with exercise and late time restricted eating (8-hour feeding period from 3 pm to 11 pm) with exercise in overweight adults.

Georgia College and State University30 participantsStarted Aug 2022

Milledgeville, Georgia, United States • Syracuse, New York, United States • Wichita Falls, Texas, United States

COMPLETED275 miles

A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects

NCT02704273

This is a pre-Phase 1 prospective, non interventional clinical assessment study to evaluate XLMTM subjects aged 3 years and younger. Many of these clinically relevant measures have not yet been routinely assessed in this population and may provide important insight on the natural history of XLMTM and for future evaluation of potential therapies.

X-linked Myotubular Myopathy

Astellas Gene Therapies34 participantsStarted Jul 2016

Los Angeles, California, United States • Gainesville, Florida, United States • Chicago, Illinois, United States +5 more locations

TERMINATEDPhase 2291 miles

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

NCT04069936

The purpose of this study is to determine the safety and efficacy of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC who are refractory or relapsing to a PD-1 containing regimen.

Non Small Cell Lung CancerLung CancerLung Cancer Metastatic+5 more

WindMIL Therapeutics19 participantsStarted Oct 2019

Duarte, California, United States • Los Angeles, California, United States • Tampa, Florida, United States +7 more locations

COMPLETED392 miles

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

NCT04976803

This study examines the correlation between ATM alterations identified using NGS profiles with ATM protein expression levels from tumor tissue assessed by IHC.

Solid Tumor, Unspecified, Adult

Artios Pharma Ltd229 participantsStarted May 2021

Oklahoma City, Oklahoma, United States • Nashville, Tennessee, United States • London, United Kingdom

TERMINATEDPhase 3392 miles

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

NCT03221842

This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).

Antibody-mediated Rejection

CSL Behring63 participantsStarted Nov 2017

Birmingham, Alabama, United States • Phoenix, Arizona, United States • San Francisco, California, United States +23 more locations

COMPLETED578 miles

Antibiotic Resistance in Global Pediatric Oncology Centers

NCT03721562

Antibiotic resistance is one of the major health threats facing global as well as domestic populations, however it is not well characterized in pediatric patients. Pediatric patients receiving cancer-directed therapy have several risk factors implicated in development of antibiotic resistance including multiple courses of antibiotics, repeated exposures to the hospital environment, indwelling devices and chemotherapy-related damage to mucosal barriers. The investigators propose to capitalize upon the unique position of St. Jude Global within the global pediatric oncology community by using its regional alliance network to describe the molecular epidemiology of antibiotic resistance in Gram-negative bacteria in this population. Primary Objectives 1. Describe the epidemiology and the phenotypic and previously determined molecular determinants of antimicrobial resistance in Gram-negative organisms isolated from pediatric diagnostic specimens in selected Central American and US sites with capacity to treat pediatric cancer 2. Utilize strain typing by whole genome sequencing to describe relatedness between organisms at participating sites

Antibiotic Resistant Infection

St. Jude Children's Research Hospital560 participantsStarted Feb 2019

Memphis, Tennessee, United States • Houston, Texas, United States • San Salvador, El Salvador +2 more locations

PreviousPage 480 of 1022Next

Diabetes

in North Carolina

Heart Diseasein North Carolina